RxDoctor Payments DataLook up a doctor →

Stuart Hetrick, DO

Neurology · Phoenix, AZNPI 1932101730

Payments from drug & device makers

$306,309in general payments, 2019–2025

Across 602 payments — averaging $508.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$100K
  • Eli Lilly$96K
  • Acadia Pharmaceuticals Inc$45K
  • AbbVie$40K
  • Novartis$18K
  • Amgen$1K
  • plus $7K from 54 others
$1,472in research payments, 2019–2025

Across 2 payments — averaging $736.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sage Therapeutics, LLC15$100,174
Eli Lilly4$96,106
Acadia Pharmaceuticals Inc7$44,620
AbbVie(2 entities)161$39,509
Novartis64$17,682
Amgen(2 entities)41$1,014
Biogen30$746
Genentech USA, Inc.13$488
Lundbeck LLC15$465
Lilly USA, LLC22$430
Sanofi16$352
UCB, Inc.20$318
CSL Behring9$300
TG Therapeutics, Inc.4$299
AstraZeneca9$287
Teva Pharmaceuticals USA, Inc.14$281
Sunovion Pharmaceuticals Inc.18$269
EMD Serono, Inc.14$193
Impel Pharmaceuticals Inc.6$190
Upsher-smith Laboratories LLC10$164
Biohaven Pharmaceuticals, Inc.3$156
Catalyst Pharmaceuticals, Inc.3$156
E.r. Squibb & Sons, L.L.C.3$149
Eisai Inc.2$137
Shire North American Group Inc1$122
Kyowa Kirin, Inc.6$122
Acorda Therapeutics, Inc7$107
Jazz Pharmaceuticals Inc.6$99
Mallinckrodt Enterprises LLC5$88
Bristol Myers Squibb5$83
Argenx US, Inc.4$82
Neurocrine Biosciences, Inc.4$80
Abbott3$72
SK Life Science, Inc.4$72
Pfizer3$70
Mallinckrodt Hospital Products Inc.4$67
Johnson & Johnson3$56
Neurelis, Inc.3$47
Amneal Pharmaceuticals LLC3$40
Biohaven Pharmaceutical Holding Company Ltd.2$38
Zyla Life Sciences, Inc.3$38
Merz North America, Inc.2$35
Promius Pharma LLC2$35
Alnylam Pharmaceuticals Inc.2$33
Nevro Corp.2$32
Bausch Health US, LLC2$31
Vertiflex, Inc.1$28
Sanofi-aventis U.S. LLC2$27
Currax Pharmaceuticals LLC2$27
Assertio Therapeutics, Inc.2$26
Akcea Therapeutics, Inc.1$24
Grifols USA, LLC1$23
ANI Pharmaceuticals, Inc.1$23
Otsuka America Pharmaceutical, Inc.1$18
GE HealthCare1$17
Banner Life Sciences, LLC1$17
Scilex Pharmaceuticals Inc.1$17
Tonix Medicines, Inc.1$16
Livanova USA, Inc.1$16
Avion Pharmaceuticals1$16

How this compares

$306,309 in reported general payments places this provider in the 85th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024
$4,639,995
Medicare patients
2,728
Services billed
304,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Phoenix

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →